Category Archives: Public Policy

Latest From Public Policy

The Presidential Inaugural: Looking Back at 30 Years of Biotech Policy Milestones

President Obama

As President Barack Obama prepares for his second inauguration, we decided that it would be a good time to take a look back on some of the most important pieces of legislation enacted by past presidential administrations and Congress with the support of the biotechnology industry. From helping create jobs, to propelling continued innovation and promoting research to find cures for rare diseases, the following pieces of legislation from the past 30 years are some Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Patently Biotech’s Top 5 Articles of 2012

By Vectorportal

2012 has been an eventful year for biotech IP issues.  Below are the top 5 articles and from Patently Biotech in 2012.  Click on the links to read the full articles. 1.  The Real Reason Why Salk Refused to Patent the Polio Vaccine A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent.  Could you patent the sun?”  Many use this statement Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here

Supreme Court - Phil Roeder

Bio IT World just published an article stating that the Myriad Supreme Court case will have little to no effect on whole genome sequencing. “As WGS involves determining the sequence of an individual’s entire genome, there is concern in many quarters that WGS could violate essentially every patent covering an isolated human DNA sequence—of which there are thousands. Indeed, this concern has been raised by scholars, policy analysts and lawyers, including before the Federal Circuit Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Public Health at Risk: Don’t Cut Programs that Work

cliff

In order to avoid the “fiscal cliff,” the Congress must compromise and protect our economic future by cutting costs and raising revenue, without compromising our nation’s support for critical government programs. Programs vital to the health of our nation – quite literally – should not suffer dramatic cuts. Making cuts to these programs could actually cost our nation more in the long run. The unintended consequences could impact our economic health, as well as our Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,